Verrica Pharmaceuticals Inc. (VRCA): Price and Financial Metrics

Verrica Pharmaceuticals Inc. (VRCA): $3.36

0.18 (+5.66%)

POWR Rating

Component Grades














  • Sentiment is the dimension where VRCA ranks best; there it ranks ahead of 97.77% of US stocks.
  • The strongest trend for VRCA is in Growth, which has been heading up over the past 179 days.
  • VRCA's current lowest rank is in the Momentum metric (where it is better than 4.51% of US stocks).

VRCA Stock Summary

  • With a year-over-year growth in debt of -96.3%, VERRICA PHARMACEUTICALS INC's debt growth rate surpasses just 1.08% of about US stocks.
  • Revenue growth over the past 12 months for VERRICA PHARMACEUTICALS INC comes in at -25.3%, a number that bests just 7.33% of the US stocks we're tracking.
  • The volatility of VERRICA PHARMACEUTICALS INC's share price is greater than that of 94.6% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to VERRICA PHARMACEUTICALS INC, a group of peers worth examining would be CORT, PDEX, BFLY, BLI, and IPWR.
  • VRCA's SEC filings can be seen here. And to visit VERRICA PHARMACEUTICALS INC's official web site, go to

VRCA Valuation Summary

  • VRCA's EV/EBIT ratio is -3; this is 134.88% lower than that of the median Healthcare stock.
  • Over the past 54 months, VRCA's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for VRCA.

Stock Date P/S P/B P/E EV/EBIT
VRCA 2022-11-25 11.9 2.4 -3.8 -3.0
VRCA 2022-11-23 12.3 2.5 -3.9 -3.2
VRCA 2022-11-22 12.8 2.6 -4.1 -3.4
VRCA 2022-11-21 11.2 2.2 -3.6 -2.8
VRCA 2022-11-18 11.1 2.2 -3.5 -2.8
VRCA 2022-11-17 10.6 2.1 -3.4 -2.6

VRCA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VRCA has a Quality Grade of D, ranking ahead of 15.27% of graded US stocks.
  • VRCA's asset turnover comes in at 0.133 -- ranking 235th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows VRCA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.133 1 -0.503
2021-03-31 0.137 1 -0.549
2020-12-31 0.000 NA -0.697
2020-09-30 0.000 NA -0.639
2020-06-30 0.000 NA -0.574
2020-03-31 0.000 NA -0.496

VRCA Price Target

For more insight on analysts targets of VRCA, see our VRCA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.86 Average Broker Recommendation 1.42 (Moderate Buy)

VRCA Stock Price Chart Interactive Chart >

Price chart for VRCA

VRCA Price/Volume Stats

Current price $3.36 52-week high $10.98
Prev. close $3.18 52-week low $1.77
Day low $3.06 Volume 117,300
Day high $3.40 Avg. volume 217,513
50-day MA $2.61 Dividend yield N/A
200-day MA $4.45 Market Cap 138.08M

Verrica Pharmaceuticals Inc. (VRCA) Company Bio

Verrica Pharmaceuticals Inc. develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790. The company is based in West Chester, Pennsylvania.

VRCA Latest News Stream

Event/Time News Detail
Loading, please wait...

VRCA Latest Social Stream

Loading social stream, please wait...

View Full VRCA Social Stream

Latest VRCA News From Around the Web

Below are the latest news stories about VERRICA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate VRCA as an investment opportunity.

Investors in Verrica Pharmaceuticals (NASDAQ:VRCA) have unfortunately lost 83% over the last three years

It's not possible to invest over long periods without making some bad investments. But you have a problem if you face...

Yahoo | November 26, 2022

H.C. Wainwright Remains a Buy on Verrica Pharmaceuticals (VRCA)

E ratio of -2.31.

Brian Anderson on TipRanks | November 14, 2022

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023 Part 1 of Phase 2 for VP-LTX-315 for Basal Cell Carcinoma on track to conclude Q1 2023 WEST CHESTER, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the third quarter ended September 30, 2022. “This quarter, we achieved

Yahoo | November 7, 2022

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference

WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 3:30 p.m. ET. Participants may access a live webcast of the event through the following link: https://journey

Yahoo | August 31, 2022

Is Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Popular Amongst Insiders?

A look at the shareholders of Verrica Pharmaceuticals Inc. ( NASDAQ:VRCA ) can tell us which group is most powerful...

Yahoo | August 17, 2022

Read More 'VRCA' Stories Here

VRCA Price Returns

1-mo 46.72%
3-mo N/A
6-mo 34.40%
1-year -63.71%
3-year -75.31%
5-year N/A
YTD -63.32%
2021 -20.42%
2020 -27.56%
2019 94.97%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6163 seconds.